A A Adjei

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi K-ras as a target for lung cancer therapy
    Alex A Adjei
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Thorac Oncol 3:S160-3. 2008
  2. ncbi Current status of pyrazoloacridine as an anticancer agent
    A A Adjei
    Mayo Clinic and Foundation, Division of Medical Oncology, Rochester, MN 55905, USA
    Invest New Drugs 17:43-8. 1999
  3. ncbi Ras signaling pathway proteins as therapeutic targets
    A A Adjei
    Mayo Clinic, Division of Medical Oncology, 200 First Street S W, Rochester, MN 55905, USA
    Curr Pharm Des 7:1581-94. 2001
  4. ncbi Gemcitabine and pemetrexed disodium combinations in vitro and in vivo
    A A Adjei
    Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Lung Cancer 34:S103-5. 2001
  5. ncbi Pharmacology and mechanism of action of pemetrexed
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lung Cancer 5:S51-5. 2004
  6. ncbi Receptor tyrosine kinase inhibitors
    P Haluska
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Opin Investig Drugs 2:280-6. 2001
  7. ncbi Novel anticancer agents in clinical development
    Alex A Adjei
    Mayo Clinic and Foundation Rochester, Minnesota 55905, USA
    Cancer Biol Ther 2:S5-15. 2003
  8. ncbi Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors
    Alex A Adjei
    Mayo Clinic and Foundation, Department of Oncology, Rochester, MN 55905, USA
    J Clin Oncol 20:1683-91. 2002
  9. ncbi An overview of farnesyltransferase inhibitors and their role in lung cancer therapy
    Alex A Adjei
    Department of Oncology, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    Lung Cancer 41:S55-62. 2003
  10. ncbi A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer
    Alex A Adjei
    Mayo Clinic and Foundation, Departments of Oncology and Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:2520-6. 2003

Detail Information

Publications102 found, 100 shown here

  1. ncbi K-ras as a target for lung cancer therapy
    Alex A Adjei
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Thorac Oncol 3:S160-3. 2008
    ..However, many of these agents have multiple targets, and their antitumor effects may not be due to K-ras inhibition. To date, no selective, specific inhibitor of the K-ras pathway is available for routine clinical use...
  2. ncbi Current status of pyrazoloacridine as an anticancer agent
    A A Adjei
    Mayo Clinic and Foundation, Division of Medical Oncology, Rochester, MN 55905, USA
    Invest New Drugs 17:43-8. 1999
    ..Because of its unique properties, combination studies with other antineoplastic agents are warranted...
  3. ncbi Ras signaling pathway proteins as therapeutic targets
    A A Adjei
    Mayo Clinic, Division of Medical Oncology, 200 First Street S W, Rochester, MN 55905, USA
    Curr Pharm Des 7:1581-94. 2001
    ..The discussion will be limited to inhibitors which are currently in human clinical trials, and include inhibitors of ras processing, inhibitors of ras protein synthesis and inhibitors of downstream ras effectors...
  4. ncbi Gemcitabine and pemetrexed disodium combinations in vitro and in vivo
    A A Adjei
    Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Lung Cancer 34:S103-5. 2001
    ..An international phase II study of this combination in non-small cell lung cancer is ongoing...
  5. ncbi Pharmacology and mechanism of action of pemetrexed
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lung Cancer 5:S51-5. 2004
    ..Tumors with codeletion of the methylthioadenosine phosphorylase gene, as a consequence of p16 deletions, may be particularly sensitive to pemetrexed. In this review, the biochemistry and mechanism of action of pemetrexed are discussed...
  6. ncbi Receptor tyrosine kinase inhibitors
    P Haluska
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Opin Investig Drugs 2:280-6. 2001
    ..The biology and results of clinical trials with these agents will be discussed...
  7. ncbi Novel anticancer agents in clinical development
    Alex A Adjei
    Mayo Clinic and Foundation Rochester, Minnesota 55905, USA
    Cancer Biol Ther 2:S5-15. 2003
    ..This review will highlight promising rationally designed, target-based agents in clinical development, as well as the unique challenges involved in their successful development...
  8. ncbi Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors
    Alex A Adjei
    Mayo Clinic and Foundation, Department of Oncology, Rochester, MN 55905, USA
    J Clin Oncol 20:1683-91. 2002
    ..To compare the pharmacokinetics of continuous venous infusion (CVI) fluorouracil (5-FU) with that of oral eniluracil/5-FU and to describe toxicities and clinical activity of prolonged oral administration of eniluracil/5-FU...
  9. ncbi An overview of farnesyltransferase inhibitors and their role in lung cancer therapy
    Alex A Adjei
    Department of Oncology, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    Lung Cancer 41:S55-62. 2003
    ..However, current evidence suggests that the antitumor activity of FTIs may be ras-independent. This article reviews preclinical and clinical data pertinent to the use of FTIs in lung cancer...
  10. ncbi A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer
    Alex A Adjei
    Mayo Clinic and Foundation, Departments of Oncology and Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:2520-6. 2003
    ..This Phase I study was undertaken to define the toxicity, pharmacodynamics, and maximum tolerated dose of the combination of R115777, a farnesyl transferase inhibitor, with gemcitabine and cisplatin in patients with advanced solid tumors...
  11. ncbi Targeting multiple signal transduction pathways in lung cancer
    Alex A Adjei
    Division of Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lung Cancer 7:S39-44. 2005
    ..These inhibitors include ZD6474, SU11248, AEE 788, sorafenib, vatalanib, and AG-013736...
  12. ncbi Pemetrexed (Alimta): a novel multitargeted antifolate agent
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 3:145-56. 2003
    ..More importantly, vitamin supplementation has not demonstrated any adverse efficacy. This review discusses the biochemistry and clinical activity of pemetrexed...
  13. ncbi Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer
    Alex A Adjei
    Department of Onclogy, Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 21:1760-6. 2003
    ..This phase II study was undertaken to define the efficacy and pharmacodynamics of R115777, a farnesyl transferase inhibitor, in the first-line treatment of patients with advanced non-small-cell lung cancer...
  14. ncbi A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Mayo Graduate School, Rochester, MN 55905, USA
    Invest New Drugs 20:297-304. 2002
    ..Subsequent studies revealed that PZA inhibits removal of platinum-DNA adducts in cultured A549 cells. Based on these results, we undertook a phase I study of the combination of PZA and carboplatin (CBDCA)...
  15. ncbi Farnesyltransferase inhibitors
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, 200 First Street S.W, Rochester, MN 55905, USA
    Cancer Chemother Biol Response Modif 20:151-67. 2002
  16. ncbi Farnesyltransferase inhibitors in breast cancer therapy
    Grace K Dy
    Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Invest 20:30-7. 2002
    ..Thus, the role of other protein targets in mediating the antitumor effect of FTIs is being elucidated. This article reviews current data on the use of FTIs in breast cancer...
  17. ncbi Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent
    Alex A Adjei
    Mayo Clinic and Foundation, Departments of Oncology, Rochester, Minnesota, USA
    Clin Cancer Res 10:4276s-4280s. 2004
    ..Low level dietary supplement of folic acid and vitamin B12 has significantly decreased the mucosal and bone marrow toxicity of pemetrexed without compromising its antitumor effect...
  18. ncbi Farnesyltransferase inhibitors
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Chemother Biol Response Modif 21:127-44. 2003
  19. ncbi Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity
    A A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN, USA
    J Clin Oncol 18:1116-23. 2000
    ....
  20. ncbi Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
    A A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 18:1748-57. 2000
    ..Multitargeted antifolate (MTA) is an investigational agent that, like gemcitabine, exhibits broad activity in solid tumors. A phase I trial of MTA and gemcitabine was undertaken, based on the demonstration of preclinical cytotoxic synergy...
  21. ncbi A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity
    A A Adjei
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 60:1871-7. 2000
    ..i.d.) but also provides the first evidence of successful inhibition of FT in the clinical setting and the first hint of clinical activity for this class of agents...
  22. ncbi Farnesyltransferase inhibitors
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Chemother Biol Response Modif 22:123-33. 2005
  23. ncbi Comparison of potential markers of farnesyltransferase inhibition
    A A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 6:2318-25. 2000
    ..Our results indicate that unprocessed HDJ-2 and prelamin A should be suitable markers of FT inhibition in clinical samples...
  24. ncbi Management of small cell cancer of the lung
    A A Adjei
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Opin Pulm Med 6:384-90. 2000
    ..Novel approaches being investigated include antibodies to factors expressed by SCLC cells and agents targeting angiogenesis, cell cycle regulation, and cell-signaling pathways...
  25. ncbi Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors
    A A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Oncol 11:1335-41. 2000
    ..MTA has also shown promising activity in a broad range of tumors in combination with other active agents such as gemcitabine and cisplatin. The clinical pharmacology, toxicity and clinical activity of MTA are reviewed in this report...
  26. ncbi Sequencing bortezomib with chemotherapy and targeted agents
    Alex A Adjei
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lung Cancer 7:S56-8. 2005
    ..This review provides an overview of selected interactions between bortezomib and other anticancer agents preclinically and in early clinical trials...
  27. ncbi The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Clin Lung Cancer 7:221-3. 2005
    ..The most promising approach to date appears to be the inhibition of mitogen-activated ERK kinase or MEK. In this review, the potential utility of MEK inhibitors in the therapy of lung cancer is discussed...
  28. ncbi Intracellular signal transduction pathway proteins as targets for cancer therapy
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5386-403. 2005
    ....
  29. ncbi Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines
    A A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 7:1438-45. 2001
    ..Additional preclinical and clinical study of this combination appears warranted...
  30. ncbi Pemetrexed (Alimta) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes
    Alex A Adjei
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Breast Cancer 3:21-3. 2002
    ..This drug combination is being evaluated in a phase II study for the treatment of metastatic breast cancer patients who have previously received a taxane and an anthracycline...
  31. ncbi Clinical studies of pemetrexed and gemcitabine combinations
    A A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Oncol 17:v29-32. 2006
    ..A recently published randomized trial of different sequences has identified the sequence of pemetrexed on day 1 followed by gemcitabine on day 1 and gemcitabine on day 8, every 21 days as the most efficacious and least toxic sequence...
  32. ncbi Novel combinations based on epidermal growth factor receptor inhibition
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:4446s-4450s. 2006
    ..A brief overview of some of these pathways (mammalian target of rapamycin, vascular endothelial growth factor receptor, and ras/mitogen-activated protein kinase signaling) is provided in this review...
  33. ncbi A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer
    Alex A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:115-23. 2003
    ..The purpose of this study was to define the toxicity, pharmacokinetics, and clinical activity of the combination of ISIS 2503, an oligodeoxynucleotide antisense inhibitor of H-ras, and gemcitabine in patients with advanced solid tumors...
  34. ncbi A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin
    R M Goldberg
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Oncol 13:1674-80. 2002
    ..This combination can be administered safely to this schedule if there is strict adherence to the 90 min infusion time for both CPT-11 and 5-FU...
  35. ncbi Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks
    S R Alberts
    Division of Medical Oncology and Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Oncol 12:627-31. 2001
    ..CONCLUSIONS: The maximum tolerated dose for this study recommended for phase II testing is gemcitabine 1000 mg/m2 and CPT-11 100 mg/m2. A partial response was seen in transitional cell carcinoma...
  36. ncbi Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566
    C Erlichman
    Mayo Clinic Cancer Center, Rochester, Minnesota, USA
    Ann Oncol 12:389-95. 2001
    ..We undertook a phase I study of BAY 12-9566, an inhibitor of MMP-2, MMP-9, and MMP-3, in patients with solid tumors to determine its safety, pharmacokinetics, and effects on potential surrogate markers of biologic activity...
  37. ncbi A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer
    Grace K Dy
    Mayo Clinic, Rochester, Minnesota, 55905, USA
    Clin Cancer Res 11:3410-6. 2005
    ..A patient with multiple myeloma had a partial response. CONCLUSION: PS-341 given 1.5 mg/m2 twice weekly for 2 of every 3 weeks is well tolerated and should be further studied...
  38. ncbi Inhibitors of the ras oncogene as therapeutic targets
    Irene M Ghobrial
    Division of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Hematol Oncol Clin North Am 16:1065-88. 2002
    ....
  39. ncbi A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
    C X Ma
    Mayo Clinic and Foundation, Department of Oncology and Medicine, Rochester, MN 55905, USA
    Ann Oncol 17:226-31. 2006
    ..Myelosuppression (66% grade 4 neutropenia and 14% febrile neutropenia) was the major treatment-related toxicity observed for this combination...
  40. ncbi Farnesyl transferase inhibitors as anticancer agents
    P Haluska
    Department of Internal Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Eur J Cancer 38:1685-700. 2002
    ..This review will discuss available clinical data on three of these agents that are currently undergoing clinical trials...
  41. ncbi A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies
    Cynthia Ma
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 59:207-15. 2007
    ..Two different treatment schedules of bortezomib in combination with paclitaxel and carboplatin were tested in this phase I study to evaluate the effects of scheduling on toxicities, pharmacodynamics and clinical activity...
  42. ncbi Preclinical and clinical studies with combinations of pemetrexed and gemcitabine
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 29:30-4. 2002
    ..Phase II studies of this combination are being performed in breast and non-small cell lung cancer. In addition, a phase III study in pancreatic cancer is ongoing...
  43. ncbi Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution
    Karin F Giordano
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Lung Cancer 49:209-15. 2005
    ....
  44. ncbi Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study
    Alan H Bryce
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Am J Clin Oncol 33:353-7. 2010
    ..Previous studies have suggested improved outcomes with a topoisomerase I inhibitor in combination with a platinum agent...
  45. ncbi Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer
    Cynthia X Ma
    Department of Oncology and Medicine, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5929-37. 2005
    ..CONCLUSION: Pemetrexed and gemcitabine administered as outlined for schedule A met the protocol-defined efficacy criteria, was less toxic compared with the other treatment schedules, and should be further evaluated...
  46. ncbi Blocking oncogenic Ras signaling for cancer therapy
    A A Adjei
    Division of Medical Oncology Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Natl Cancer Inst 93:1062-74. 2001
    ..Novel cancer therapeutic approaches based on the inhibition of Ras-mediated signaling, including inhibition of Ras processing, inhibition of Ras protein synthesis, and blockage of downstream Ras effectors, will be discussed...
  47. ncbi A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors
    Grace K Dy
    Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 55:522-30. 2005
    ..Eight patients had disease stabilization for five or more cycles. CONCLUSION: Gemcitabine immediately followed by pemetrexed is well tolerated and clinically active, and deserves further evaluation in phase II trials...
  48. ncbi Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways
    Chunrong Yu
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Mol Cancer Ther 5:2378-87. 2006
    ..Further clinical development of this combination seems warranted...
  49. ncbi A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)
    A Jatoi
    Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Ann Oncol 21:2040-4. 2010
    ..Non-small-cell lung cancer (NSCLC) is a disease of the elderly. Seeking a tolerable but effective regimen, we tested cetuximab + radiation in elderly and/or poor performance status patients with locally advanced NSCLC...
  50. ncbi Gemcitabine and Pemetrexed disodium in treating breast cancer
    A A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Oncology (Williston Park) 15:34-7. 2001
    ..Pemetrexed disodium has also shown clinically relevant activity in combination with gemcitabine (Gemzar). This combination is being evaluated for the treatment of metastatic breast cancer...
  51. ncbi A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study
    G K Dy
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 16:1811-6. 2005
    ....
  52. ncbi A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer
    E A Perez
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Ann Oncol 13:1225-35. 2002
    ....
  53. ncbi Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd)
    E Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Oncol 12:701-7. 2001
    ..Evidence of potential antitumor activity was observed: 1 patient (with colon cancer) had a partial response while 15 others had stable disease...
  54. ncbi A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer
    Grace K Dy
    Department of Oncology, Division of Medical Oncology, Mayo Clinic and Foundation, 200 First St. SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 56:623-8. 2005
    ..Although prolonged disease stabilization was achieved in some patients, we do not recommend combining celecoxib with docetaxel and irinotecan because of lack of activity and the side effect profile of this combination...
  55. ncbi The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy
    Julian R Molina
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Clin Lung Cancer 5:21-7. 2003
    ..In this review, the pharmacology and clinical activity of pemetrexed in NSCLC cancer is discussed...
  56. ncbi Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells
    Chunrong Yu
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Neuro Oncol 10:309-19. 2008
    ..This combination regimen warrants further preclinical and possible clinical study for glioma patients...
  57. ncbi Advances in systemic therapy of small cell cancer of the lung
    G A Daniels
    Division of Medical Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 1:211-21. 2001
    ..This review outlines current treatment strategies, summarizes recent clinical trials and offers a view of what the next 5 years may hold for the treatment of small cell lung cancer...
  58. ncbi Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
    V Ramakrishnan
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Oncogene 29:1190-202. 2010
    ..Sorafenib, through multiple mechanisms exerts potent anti-myeloma activity and these results favor further clinical evaluation and development of novel sorafenib combinations...
  59. ncbi Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
    Bret B Friday
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Clin Cancer Res 14:342-6. 2008
    ..Herein, we review the MAPK pathway, the development of small-molecule MEK inhibitors, and the results obtained to date with MEK inhibitors in human cancer trials...
  60. ncbi Immunohistochemical assays of farnesyltransferase inhibition in patient samples
    Alex A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN, USA
    Methods Mol Med 85:141-5. 2003
  61. ncbi Novel pharmacological agents in clinical development for solid tumours
    G K Dy
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Investig Drugs 10:2059-88. 2001
    ..Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review...
  62. ncbi The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation
    Jin Ping Lai
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN, USA
    Hepatology 52:1680-9. 2010
    ..CONCLUSION: Together, these findings identify a novel mechanism mediating the oncogenic function of SULF2 in HCC that includes GPC3-mediated activation of Wnt signaling via the Wnt3a/glycogen synthase kinase 3 beta axis...
  63. ncbi Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation
    Chunrong Yu
    Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Clin Cancer Res 13:1140-8. 2007
    ....
  64. ncbi Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization
    Xue Wei Meng
    Divisions of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 282:29831-46. 2007
    ..Collectively, these observations not only suggest a model in which Mcl-1 confers TRAIL resistance by serving as a buffer for Bak, Bim, and Puma, but also identify sorafenib as a potential modulator of TRAIL sensitivity...
  65. ncbi A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer
    Julian R Molina
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer Invest 24:382-9. 2006
    ..6 months and 7.5 months, respectively. CONCLUSION: This second-line treatment regimen of irinotecan and docetaxel in NSCLC patients has shown activity, but can not be recommended over single-agent regimens because of significant toxicity...
  66. ncbi The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006
    Chunrong Yu
    Division of Medical Oncology, Mayo Clinic, 200 First Street. SW, Rochester, MN 55905, USA
    Oncogene 24:6861-9. 2005
    ..Conversely, Mcl-1 downregulation by short hairpin RNA enhanced BAY 43-9006-induced apoptosis. Collectively, these findings demonstrate that drug-induced Mcl-1 downregulation contributes to the proapoptotic effects of BAY 43-9006...
  67. ncbi A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer
    Grace K Dy
    Department of Oncology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 11:1877-83. 2005
    ..There was no correlation between dose level and accumulation of unfarnesylated HDJ-2 in PBMCs nor tumor response...
  68. ncbi Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis
    S E Schild
    Department of Radiation Oncology, Mayo Clinic, Scottsdale, USA
    Ann Oncol 23:2919-24. 2012
    ....
  69. ncbi Systemic chemotherapy in patients with renal failure
    L Bekele
    Mayo Medical School, Rochester, Minnesota, USA
    Am J Clin Oncol 24:382-4. 2001
    ..The data on systemic chemotherapy in patients with severe renal dysfunction are reviewed...
  70. ncbi Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine
    Charles L Loprinzi
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Palliat Med 8:924-30. 2005
    ....
  71. ncbi Pathophysiology and treatment of hot flashes
    Tait D Shanafelt
    Department of Oncology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:1207-18. 2002
    ..The use of clonidine, methyldopa, and belladonna should be discouraged because of their modest efficacy and adverse effects...
  72. ncbi Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)
    Elizabeth A Johnson
    Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Lung Cancer 60:200-7. 2008
    ....
  73. ncbi Pemetrexed in the treatment of selected solid tumors
    Alex A Adjei
    Division of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 29:50-3. 2002
    ..In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed...
  74. ncbi A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021
    Scott H Okuno
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 112:1772-9. 2008
    ....
  75. ncbi Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
    Julian R Molina
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:584-94. 2008
    ....
  76. ncbi A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors
    Henry C Pitot
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:712-7. 2002
    ..To evaluate the toxicities, characterize the pharmacokinetics, and determine the maximum-tolerated dose of bizelesin administered once every 4 weeks...
  77. ncbi Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data
    Julian R Molina
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:7900-8. 2008
    ..The present studies were done to determine the effect of combining topotecan and the dual epidermal growth factor receptor/HER2 inhibitor lapatinib in tissue culture, a murine xenograft model, and a phase I clinical trial...
  78. ncbi Novel agents on the horizon for cancer therapy
    Wen W Ma
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    CA Cancer J Clin 59:111-37. 2009
    ..This review also highlights the pipeline of rationally designed drugs in clinical development that have the potential to impact clinical care in the near future...
  79. ncbi Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study
    Ping Yang
    College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Thorac Oncol 4:479-85. 2009
    ....
  80. ncbi Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials
    Nathan R Foster
    Division of Biomedical Statistics and Informatics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 115:2721-31. 2009
    ....
  81. ncbi The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:363-8. 2007
    ....
  82. ncbi Advances in chemotherapy of non-small cell lung cancer
    Julian R Molina
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Chest 130:1211-9. 2006
    ....
  83. ncbi Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:2349-54. 2005
    ..No difference in survival was identified between the two arms. The current analysis examined the relation between age and outcome for patients treated during this trial...
  84. ncbi SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma
    Jin-Ping Lai
    Center for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 130:2130-44. 2006
    ..CONCLUSIONS: These results show that SULF1 promotes histone H4 acetylation, potentiates the effects of HDAC inhibitors, and inhibits HCC tumorigenesis...
  85. ncbi A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials
    Sumithra J Mandrekar
    Mayo Clinic College of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 107:781-92. 2006
    ....
  86. ncbi Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors
    Charles Erlichman
    Department of Oncology, Mayo Clinic, Rochester, MN 55902, USA
    J Clin Oncol 24:2252-60. 2006
    ....
  87. ncbi Introduction to a cancer symposium for the practitioner
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1085-6. 2005
  88. ncbi A phase II study of bortezomib in the treatment of metastatic malignant melanoma
    Svetomir N Markovic
    Melanoma Study Group, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:2584-9. 2005
    ..Bortezomib is a proteasome inhibitor with manageable clinical toxicity and laboratory evidence of anti-melanoma activity. Therefore, it was considered for clinical testing in patients with metastatic melanoma...
  89. ncbi Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors
    Matthew P Goetz
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:3761-9. 2003
    ..Additionally, we investigated the effect of CPT-11 on oxaliplatin pharmacokinetics...
  90. ncbi The Ras/Raf/MAPK pathway
    Julian R Molina
    Division of Medical Oncology Mayo Clinic, Rochester, MN 55905, USA
    J Thorac Oncol 1:7-9. 2006
  91. ncbi The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours
    L F Porrata
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Cancer 85:484-9. 2001
    ..The pharmacologic evidence for the use of other antineoplastic agents for HDT in solid tumours is non-existent. More preclinical studies are needed for a rational development of this therapeutic approach for solid tumours...
  92. ncbi Signal transduction pathway targets for anticancer drug discovery
    A A Adjei
    Mayo Clinic, Division of Medical Oncology, 200 First Street S W, Rochester, MN 55905, USA
    Curr Pharm Des 6:361-78. 2000
    ....
  93. ncbi Human 3'-phosphoadenosine 5'-phosphosulfate synthetase: radiochemical enzymatic assay, biochemical properties, and hepatic variation
    Z Xu
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical Foundation, Rochester, MN 55905 0001, USA
    Drug Metab Dispos 29:172-8. 2001
    ..An 18-fold variation was observed. This sensitive new radiochemical assay can now be used in pharmacogenetic studies of PAPSS in humans...
  94. ncbi A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer
    E Claire Dees
    Division of Hematology and Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Invest New Drugs 21:75-84. 2003
    ..Pharmacokinetic analysis showed that sequence does not impact on the pharmacokinetics of PZA when given in combination with cisplatin...
  95. ncbi Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
    Corey J Langer
    Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Clin Lung Cancer 9:85-91. 2008
    ..These efforts focus on radiation dose escalation using image-guided radiation therapy as well as newer cytotoxic agents (eg, pemetrexed) and targeted therapies (eg, cetuximab, bevacizumab, and etc) thus far unexplored in this setting...
  96. ncbi What is the right dose? The elusive optimal biologic dose in phase I clinical trials
    Alex A Adjei
    J Clin Oncol 24:4054-5. 2006
  97. ncbi Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
    Alex A Adjei
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Clin Oncol 26:2139-46. 2008
    ..To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer...
  98. ncbi Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
    John Rinehart
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Clin Oncol 22:4456-62. 2004
    ....
  99. ncbi Farnesyltransferase inhibitors
    Said M Sebti
    H. Lee Moffitt Cancer Center, Tampa, FL, USA
    Semin Oncol 31:28-39. 2004
    ..Activity has been shown in hematologic malignancies (acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome), breast cancer, and glioma. Several combination studies of FTIs and standard cytotoxic agents are ongoing...
  100. ncbi Novel small-molecule inhibitors of the vascular endothelial growth factor receptor
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Lung Cancer 8:S74-8. 2007
    ..There are several small-molecule inhibitors of tyrosine kinase activity of VEGF receptors in clinical trials. These are discussed in this review...
  101. ncbi Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 13:2684-91. 2007
    ..To evaluate the combination of sorafenib and gefitinib in patients with advanced non-small cell lung cancer...